Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PVT201
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Avance Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 29, 2025
Lead Product(s) : PVT201
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Avance Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PVT401
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Recipient : Resilience
Deal Size : Undisclosed
Deal Type : Partnership
Resilience Partners with Parvus for PVT401 Development in Autoimmune Disease
Details : The partnership aims to support the development and manufacturing of Parvus novel autoimmune drug candidate, PVT401, targeting Inflammatory Bowel Disease.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 08, 2025
Lead Product(s) : PVT401
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Recipient : Resilience
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : PVT-401
Therapeutic Area : Gastroenterology
Study Phase : Preclinical
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Collaboration
Parvus Collaborates with AbbVie to Develop IBD Therapies Using Navacim Technology
Details : AbbVie partners with Parvus to develop immunotherapies for Inflammatory Bowel Disease (IBD) using Parvus' Navacim Treg platform, including PVT-401.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
March 20, 2024
Lead Product(s) : PVT-401
Therapeutic Area : Gastroenterology
Highest Development Status : Preclinical
Sponsor : AbbVie Inc
Deal Size : Undisclosed
Deal Type : Collaboration